Equities research analysts predict that Genocea Biosciences Inc (NASDAQ:GNCA) will report earnings of ($0.45) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.56). Genocea Biosciences reported earnings of ($0.72) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 37.5%. The business is expected to announce its next earnings results on Thursday, November 7th.
According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.13). For the next financial year, analysts expect that the business will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.87) to ($1.21). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.02).
Shares of GNCA stock traded down $0.03 during trading hours on Wednesday, hitting $3.07. 3,380 shares of the company were exchanged, compared to its average volume of 374,586. The stock has a market cap of $80.28 million, a price-to-earnings ratio of -0.83 and a beta of 2.40. Genocea Biosciences has a 1 year low of $2.24 and a 1 year high of $11.28. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.96 and a current ratio of 5.96. The business’s fifty day moving average price is $3.58.
In other news, major shareholder Peter W. Sonsini purchased 2,857,142 shares of the stock in a transaction on Monday, June 24th. The shares were acquired at an average price of $3.50 per share, for a total transaction of $9,999,997.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.33% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wedbush Securities Inc. acquired a new stake in Genocea Biosciences in the 2nd quarter worth approximately $43,000. Wells Fargo & Company MN raised its position in shares of Genocea Biosciences by 271.9% during the second quarter. Wells Fargo & Company MN now owns 33,631 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 24,587 shares during the period. DRW Securities LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $118,000. Monashee Investment Management LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $392,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Genocea Biosciences during the second quarter worth about $526,000.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Further Reading: Strike Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.